ArticleThe pharmacogenomics journal2016
A subset of genetic susceptibility variants for colorectal cancer also has prognostic value.
Article in The pharmacogenomics journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Colorectal Cancer Risk Loci: Prognostic Factors for Clinical Outcomes? A Systematic Review and Meta-Analysis.Cancer reports (Hoboken, N.J.) · 2025Pooled it
- Unveiling the link: Evaluating MTHFR gene polymorphisms and colorectal cancer risk through meta-analysis.PloS one · 2025Pooled it
- Methylenetetrahydrofolate reductase C677T polymorphism and colorectal cancer susceptibility: a meta-analysis.Bioscience reports · 2017Pooled it
- SMAD7 polymorphisms and colorectal cancer risk: a meta-analysis of case-control studies.Oncotarget · 2016Pooled it
- Glutathione-Dependent Pathways in Cancer Cells.International journal of molecular sciences · 2024Review
- Advances in the role of GPX3 in ovarian cancer (Review).International journal of oncology · 2024Article
- The progress of protein synthesis factors eIFs, eEFs and eRFs in inflammatory bowel disease and colorectal cancer pathogenesis.Frontiers in oncology · 2022Review
- Prognosis Prediction for Colorectal Cancer Patients: A Risk Score Based on The Metabolic-Related Genes.International journal of medical sciences · 2021Article
- Review
- Identifying Transcriptomic Signatures and Rules for SARS-CoV-2 Infection.Frontiers in cell and developmental biology · 2020Article
- Effects ofNeuropsychiatric disease and treatment · 2020Article
- Single Nucleotide Polymorphism in SMAD7 and CHI3L1 and Colorectal Cancer Risk.Mediators of inflammation · 2018Review
- Complex genetic control of lung tumorigenesis in resistant mice strains.Cancer science · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We investigated the possible influence of 86 single-nucleotide polymorphisms (SNPs), known to associate with the risk of colorectal cancer (CRC), on overall survival and time to recurrence (TTR) in 733 Italian CRC patients followed up for up to 84 months after surgery. In the Cox multivariate analysis, adjusted for gender, age, pathological stage and adjuvant chemotherapy (yes/no), the risk of death significantly increased by rare allele count (P<0.05) for rs1801133 (MTHFR), rs4939827 (SMAD7), rs2306283 (SLCO1B1) and rs12898159 (BMP4), whereas for rs736775 (GPX3) the opposite was observed. Two additional SNPs associated with TTR, namely rs16892766 (downstream of EIF3H) and rs10749971 (COLCA2). Our findings show that some genetic variants previously found to associate with CRC risk are also associated with survival after treatment. The identification of alleles defining subgroups of patients with worse clinical outcome may have application in developing pharmacogenetic strategies aimed at personalizing CRC treatment.
Indexed as
Identifiers
25963333What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.